Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
Cancer immunotherapy utilizes vaccines targeting tumor antigens or tumor endothelium to prevent or regress tumors. Many cancer vaccines are designed to induce antigen-specific effector T cells that migrate to the tumor site. In an optimal situation, the effector T cells penetrate the tumor, release their effector molecules, induce tumor cell death and tumor regression. However, the tumor microenvironment is frequently immunosuppressive and contributes to a state of immune ignorance, impacting on the vaccine's ability to break tolerance to tumor antigen/s. This review discusses the factors in the tumor microenvironment that can affect the efficacy of cancer vaccines. In particular, the review focuses on pathways leading to effector T cell penetration of tumors or the inhibition of this process.
Neeson
Paul
P
Microbiology Department, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6076, USA.
Paterson
Yvonne
Y
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D002634:Chemotaxis, Leukocyte / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D050794:STAT1 Transcription Factor / Q000276:immunology; D050796:STAT3 Transcription Factor / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D050794:STAT1 Transcription Factor; D050796:STAT3 Transcription Factor; D007371:Interferon-gamma